Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report ; volume:8 ; number:1 ; day:23 ; month:10 ; year:2014 ; pages:1-3 ; date:12.2014
Journal of medical case reports ; 8, Heft 1 (23.10.2014), 1-3, 12.2014
- Urheber
-
Noriega Aldave, Adrian P.
- Beteiligte Personen und Organisationen
-
Jaiswal, Shikha
SpringerLink (Online service)
- DOI
-
10.1186/1752-1947-8-353
- URN
-
urn:nbn:de:1111-201607113384
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Noriega Aldave, Adrian P.
- Jaiswal, Shikha
- SpringerLink (Online service)
Ähnliche Objekte (12)
Zoledronic acid targets chemo-resistant polyploid giant cancer cells
Multiple myeloma
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Imaging of Multiple Myeloma
Severe abdominal pain and diarrhea – unusual multiple myeloma presentation with a severe prognosis: a case report
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
New therapies in multiple myeloma
Leptomeningeal metastasis of multiple myeloma
Zoledronic acid targets chemo-resistant polyploid giant cancer cells
Multiple myeloma
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Imaging of Multiple Myeloma
Severe abdominal pain and diarrhea – unusual multiple myeloma presentation with a severe prognosis: a case report
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
New therapies in multiple myeloma
Leptomeningeal metastasis of multiple myeloma
Zoledronic acid targets chemo-resistant polyploid giant cancer cells
Multiple myeloma
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Imaging of Multiple Myeloma
Severe abdominal pain and diarrhea – unusual multiple myeloma presentation with a severe prognosis: a case report
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
New therapies in multiple myeloma